acute myeloid leukemia RNAi screening of the tyrosine kinome identifies therapeutic targets in

摘要: Abstract Despite vast improvements in our understanding of cancer genetics, a large percentage cases present without knowledge the causative genetic events. Tyrosine kinases are frequently implicated pathogenesis numerous types cancer, but identification and validation tyrosine kinase targets can be time-consuming process. We report establishment an efficient, functional screening assay using RNAi technology to directly assess compare effect individually targeting each member family. demonstrate that siRNA identify containing activating mutations Janus (JAK) 3 (A572V) CMK cells c-KIT (V560G) HMC1.1 cells. In addition, this identifies do not contain mutations, such as JAK1 focal adhesion (FAK), crucial survival This technique, with additional development, may eventually offer potential match specific therapies individual patients based on assay. Keywords: AML, targeted therapy, molecular diagnosis From bloodjournal.hematologylibrary.org by guest June 12, 2013. For personal use only.